Lymphoma: Brentuximab vedotin and involved site radiotherapy in newly diagnosed, unfavorable
risk Hodgkin lymphoma.
Will treatment with a new drug, brentuximab vedotin (BV), combined with adriamycin,
vinblastine, and dacarbazine (AVD) chemotherapy followed by radiation improve the
ability to cure more patients with Hodgkin Lymphoma?
Basic Study Information
Purpose:Location: Cancer Center
Early stage, high risk HL has a chance of coming back after standard treatment. The
best treatment for early stage, high risk HL is chemotherapy followed by radiation.
The chemotherapy is called ABVD and has four drugs approved by the Food and Drug Administration
(FDA): doxorubicin, bleomycin, vinblastine, and dacarbazine. This is a pilot phase
II study of a new treatment plan for your HL. The treatment consists of a new drug,
brentuximab vedotin (BV), combined with adriamycin, vinblastine, and dacarbazine (AVD)
chemotherapy followed by radiation. The purpose of this study is to find out whether
BV with AVD chemotherapy and radiation is a safe and effective treatment. BV is a
type of drug called an antibody drug conjugate. BV has 2 parts; a part that targets
cancer cells (the antibody) and a cell killing part (the chemotherapy). The antibody
part of BV sticks to a target called CD30. CD30 is an important molecule on HL cancer
cells and some normal cells of the immune system. The cell killing part of BV is a
chemotherapy called monomethyl auristatin E (MMAE). It can kill cells that the antibody
part of BV sticks to.
Study Web URL: http://clinicaltrials.gov/ct2/show/NCT01868451?term=Brentuximab+Vedotin+Combined+with+AVD+Chemotherapy+and+30+Gray&rank=1
Study Reference #: ULYM-14035
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Yelena Lerman
Phone: (585) 276-8333
Additional Study Details
Learn More About These Conditions
More information about Lymphoma
Trial Not Found
The study you are looking for is not active at this time.
Return to Search